RANI Stock — Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings Inc (RANI)

Updated October 16, 2026.

RANI is a Stock. Total return is -94.2% over the past 5.2 years, 180.9 points behind SPY at 86.7%.

Rani Therapeutics Holdings is a clinical-stage biotherapeutics company developing an oral delivery platform called RaniPill to administer biologics and drugs by capsule instead of injection. The company's pipeline includes candidates in preclinical and discovery stages for rheumatoid arthritis, obesity, rare diseases, and inflammatory conditions, along with partnerships for hemophilia and obesity treatments. As an early-stage development company, it does not currently distribute dividends.

RANI performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.2% over the past 5.2 years, 180.9 points behind SPY at 86.7%. Over the past year its total return — price change plus distributions reinvested — is 36.0%. Its deepest 1-year drawdown was 77.8%.

RANI key facts

Asset type

Stock

Asset class

Equity

Inception date

07/30/2021

Distribution frequency

None

Last close

$0.64 (as of 2026-10-16)

Market cap

$73,941,229

Average volume

589110.0

Beta

0.706

Payout ratio

0.0%

EPS

$-0.13

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RANI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 77.8%.

Who may consider RANI — and who may not

It is a weaker fit for investors who need monthly cash flow (RANI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RANI

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions